Novo Nordisk Shuffles the Deck: 9,000 Layoffs and Remote Work Ends Amid Competitive Restructuring
Novo Nordisk, the pharmaceutical giant known for its diabetes and obesity treatments, has announced a massive restructuring that includes 9,000 job cuts worldwide and the end of its remote work policy by 2026. This move comes as the company battles increased competition in the obesity drug market, notably from Eli Lilly, and attempts to streamline operations for a leaner, more nimble corporate structure.
Sep 12